Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2008-10

AUTHORS

Michael J. Overman, Gauri Varadhachary, Scott Kopetz, Melanie B. Thomas, Masakazu Fukushima, Keizo Kuwata, Akira Mita, Robert A. Wolff, Paulo M. Hoff, Henry Xiong, James L. Abbruzzese

ABSTRACT

This study was designed to determine the safety and optimal dosing of TAS-102, a novel oral combination of alphaalphaalpha-trifluorothymidine (FTD) and an inhibitor of thymidine phoshorylase, in patients with solid tumors. Patients who met the eligibility criteria were treated with one of two different TAS-102 regimens: once per day on either days 1-5 and 8-12 every 4 weeks (schedule A) or days 1-5 every 3 weeks (schedule B). The primary objectives were the determination of the maximum tolerated dose, dose-limiting toxicities (DLTs), and recommended phase II dose. Pharmacokinetic analysis was conducted during courses 1 and 2. Sixty-three patients received a total of 172 courses of therapy with the median number of courses delivered on both schedules being 2. DLTs were observed in three patients on schedule A, 70 mg/m(2)/day (1) and 110 mg/m(2)/day (2); and in five patients on schedule B, 120 mg/m(2)/day (1), 170 mg/m(2)/day (2), 180 mg/m(2)/day (2). Granulocytopenia was the DLT in seven of the eight cases. The most frequent toxicities were nausea, fatigue, granulocytopenia, anemia, diarrhea, and abdominal pain. Twelve patients, 6 on schedule A and 6 on schedule B, were treated at the recommended phase II dose, with good tolerance. No objective responses were seen in this heavily pretreated, 5-FU-refractory population. The pharmacokinetic parameters of FTD are a T (max) of 0.53 to 3.15 h, t (1/2) of 1.46 to 4.20 h, volume of distribution of 0.0526 to 0.483 l/kg, and clearance of 0.0194 to 0.197 1/h/kg. The recommended phase II doses for TAS-102 are 100 mg/m(2)/day on schedule A and 160 mg/m(2)/day on schedule B. Future development of TAS-102 should focus upon multiple daily dosing schedules. More... »

PAGES

445-454

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-008-9142-3

DOI

http://dx.doi.org/10.1007/s10637-008-9142-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1011874287

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/18528634


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Combinations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Maximum Tolerated Dose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Trifluridine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Uracil", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston Texas, 1515 Holcombe Blvd., 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Overman", 
        "givenName": "Michael J.", 
        "id": "sg:person.01231377053.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231377053.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston Texas, 1515 Holcombe Blvd., 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Varadhachary", 
        "givenName": "Gauri", 
        "id": "sg:person.01051756026.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051756026.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston Texas, 1515 Holcombe Blvd., 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kopetz", 
        "givenName": "Scott", 
        "id": "sg:person.01320500077.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320500077.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston Texas, 1515 Holcombe Blvd., 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thomas", 
        "givenName": "Melanie B.", 
        "id": "sg:person.015275452707.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015275452707.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Taiho Pharmaceutical (Japan)", 
          "id": "https://www.grid.ac/institutes/grid.419828.e", 
          "name": [
            "Taiho Pharmaceutical Co. LTD., Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fukushima", 
        "givenName": "Masakazu", 
        "id": "sg:person.01144105331.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01144105331.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Taiho Pharmaceutical (Japan)", 
          "id": "https://www.grid.ac/institutes/grid.419828.e", 
          "name": [
            "Taiho Pharmaceutical Co. LTD., Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kuwata", 
        "givenName": "Keizo", 
        "id": "sg:person.0740127427.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740127427.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Taiho Pharmaceutical (Japan)", 
          "id": "https://www.grid.ac/institutes/grid.419828.e", 
          "name": [
            "Taiho Pharmaceutical Co. LTD., Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mita", 
        "givenName": "Akira", 
        "id": "sg:person.01006242627.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006242627.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston Texas, 1515 Holcombe Blvd., 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wolff", 
        "givenName": "Robert A.", 
        "id": "sg:person.01133335751.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133335751.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital S\u00edrio-Liban\u00eas", 
          "id": "https://www.grid.ac/institutes/grid.413471.4", 
          "name": [
            "Centro Oncol\u00f3gico de Hospital Sirio-Liban\u00e9s, Sao Paulo, Brazil"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hoff", 
        "givenName": "Paulo M.", 
        "id": "sg:person.0635347013.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0635347013.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Center for Cancer and Blood Disorders", 
          "id": "https://www.grid.ac/institutes/grid.477919.5", 
          "name": [
            "The Center for Cancer and Blood Disorders, ForthWorth, Texas, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xiong", 
        "givenName": "Henry", 
        "id": "sg:person.016444546257.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016444546257.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston Texas, 1515 Holcombe Blvd., 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Abbruzzese", 
        "givenName": "James L.", 
        "id": "sg:person.0645263515.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645263515.62"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1002/cncr.22125", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002118474"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(98)00058-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004034553"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1074", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012947440", 
          "https://doi.org/10.1038/nrc1074"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1074", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012947440", 
          "https://doi.org/10.1038/nrc1074"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-005-0033-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022076717", 
          "https://doi.org/10.1007/s00280-005-0033-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-005-0033-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022076717", 
          "https://doi.org/10.1007/s00280-005-0033-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02490095", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022217340", 
          "https://doi.org/10.1007/bf02490095"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02490095", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022217340", 
          "https://doi.org/10.1007/bf02490095"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00001813-200503000-00007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028679966"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00001813-200503000-00007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028679966"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002800050043", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030921918", 
          "https://doi.org/10.1007/s002800050043"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1349-7006.2007.00477.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033925038"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002800000243", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047992042", 
          "https://doi.org/10.1007/s002800000243"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049278910"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2174/1568011043482089", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1069191995"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3892/ijmm.13.2.249", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071505637"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3892/ijmm.13.4.545", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071505677"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3892/ijo.25.3.571", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071515444"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3892/ijo.27.2.449", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071515804"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3892/or.11.2.381", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071529095"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1992.10.6.896", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1076886243"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1080229750", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2008-10", 
    "datePublishedReg": "2008-10-01", 
    "description": "This study was designed to determine the safety and optimal dosing of TAS-102, a novel oral combination of alphaalphaalpha-trifluorothymidine (FTD) and an inhibitor of thymidine phoshorylase, in patients with solid tumors. Patients who met the eligibility criteria were treated with one of two different TAS-102 regimens: once per day on either days 1-5 and 8-12 every 4 weeks (schedule A) or days 1-5 every 3 weeks (schedule B). The primary objectives were the determination of the maximum tolerated dose, dose-limiting toxicities (DLTs), and recommended phase II dose. Pharmacokinetic analysis was conducted during courses 1 and 2. Sixty-three patients received a total of 172 courses of therapy with the median number of courses delivered on both schedules being 2. DLTs were observed in three patients on schedule A, 70 mg/m(2)/day (1) and 110 mg/m(2)/day (2); and in five patients on schedule B, 120 mg/m(2)/day (1), 170 mg/m(2)/day (2), 180 mg/m(2)/day (2). Granulocytopenia was the DLT in seven of the eight cases. The most frequent toxicities were nausea, fatigue, granulocytopenia, anemia, diarrhea, and abdominal pain. Twelve patients, 6 on schedule A and 6 on schedule B, were treated at the recommended phase II dose, with good tolerance. No objective responses were seen in this heavily pretreated, 5-FU-refractory population. The pharmacokinetic parameters of FTD are a T (max) of 0.53 to 3.15 h, t (1/2) of 1.46 to 4.20 h, volume of distribution of 0.0526 to 0.483 l/kg, and clearance of 0.0194 to 0.197 1/h/kg. The recommended phase II doses for TAS-102 are 100 mg/m(2)/day on schedule A and 160 mg/m(2)/day on schedule B. Future development of TAS-102 should focus upon multiple daily dosing schedules.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10637-008-9142-3", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "26"
      }
    ], 
    "name": "Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors", 
    "pagination": "445-454", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-008-9142-3"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "3893836ec0ba774403f525af3d26a7a8faa1b78f5d4639f8dcdc13e77c3ca8bf"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1011874287"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "18528634"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-008-9142-3", 
      "https://app.dimensions.ai/details/publication/pub.1011874287"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-15T09:19", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000376_0000000376/records_56179_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs10637-008-9142-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-008-9142-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-008-9142-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-008-9142-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-008-9142-3'


 

This table displays all metadata directly associated to this object as RDF triples.

266 TRIPLES      21 PREDICATES      62 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-008-9142-3 schema:about N10b8ee3a668f46718512b14e953915e3
2 N1311e2da408c4c219674362ecb84eb9f
3 N2329152b72384a4690fda62444762aa9
4 N2e1057ef6835405baa20da585875e81a
5 N311fac97838f47d88baaa73a2f57533e
6 N5870ad86ceda49dd9f306ec27fd6493d
7 N6f3e2579bbd44c9bab0760da9a1df036
8 Na5a12c413a88432fa1e20e8c95e06674
9 Naba4d4793ad640c8923582504ece4367
10 Nae2bf377506e4a01b64c9cd1aac35094
11 Nb5826843b39649e5a1dc6ecd892a843e
12 Nc4aa3506e14f4835b8de803cfd83ac54
13 Nd7c47d5bdd2748338a14d626d3602e4b
14 Ndbd43bc5390a4e0a88abe7261be5d070
15 Nf5de1b83de6f46138d478b9f6a704ff8
16 anzsrc-for:11
17 anzsrc-for:1103
18 schema:author N0d282af2738740d0914a7298c55ede19
19 schema:citation sg:pub.10.1007/bf02490095
20 sg:pub.10.1007/s00280-005-0033-4
21 sg:pub.10.1007/s002800000243
22 sg:pub.10.1007/s002800050043
23 sg:pub.10.1038/nrc1074
24 https://app.dimensions.ai/details/publication/pub.1080229750
25 https://doi.org/10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6
26 https://doi.org/10.1002/cncr.22125
27 https://doi.org/10.1016/s0959-8049(98)00058-6
28 https://doi.org/10.1097/00001813-200503000-00007
29 https://doi.org/10.1111/j.1349-7006.2007.00477.x
30 https://doi.org/10.1200/jco.1992.10.6.896
31 https://doi.org/10.2174/1568011043482089
32 https://doi.org/10.3892/ijmm.13.2.249
33 https://doi.org/10.3892/ijmm.13.4.545
34 https://doi.org/10.3892/ijo.25.3.571
35 https://doi.org/10.3892/ijo.27.2.449
36 https://doi.org/10.3892/or.11.2.381
37 schema:datePublished 2008-10
38 schema:datePublishedReg 2008-10-01
39 schema:description This study was designed to determine the safety and optimal dosing of TAS-102, a novel oral combination of alphaalphaalpha-trifluorothymidine (FTD) and an inhibitor of thymidine phoshorylase, in patients with solid tumors. Patients who met the eligibility criteria were treated with one of two different TAS-102 regimens: once per day on either days 1-5 and 8-12 every 4 weeks (schedule A) or days 1-5 every 3 weeks (schedule B). The primary objectives were the determination of the maximum tolerated dose, dose-limiting toxicities (DLTs), and recommended phase II dose. Pharmacokinetic analysis was conducted during courses 1 and 2. Sixty-three patients received a total of 172 courses of therapy with the median number of courses delivered on both schedules being 2. DLTs were observed in three patients on schedule A, 70 mg/m(2)/day (1) and 110 mg/m(2)/day (2); and in five patients on schedule B, 120 mg/m(2)/day (1), 170 mg/m(2)/day (2), 180 mg/m(2)/day (2). Granulocytopenia was the DLT in seven of the eight cases. The most frequent toxicities were nausea, fatigue, granulocytopenia, anemia, diarrhea, and abdominal pain. Twelve patients, 6 on schedule A and 6 on schedule B, were treated at the recommended phase II dose, with good tolerance. No objective responses were seen in this heavily pretreated, 5-FU-refractory population. The pharmacokinetic parameters of FTD are a T (max) of 0.53 to 3.15 h, t (1/2) of 1.46 to 4.20 h, volume of distribution of 0.0526 to 0.483 l/kg, and clearance of 0.0194 to 0.197 1/h/kg. The recommended phase II doses for TAS-102 are 100 mg/m(2)/day on schedule A and 160 mg/m(2)/day on schedule B. Future development of TAS-102 should focus upon multiple daily dosing schedules.
40 schema:genre research_article
41 schema:inLanguage en
42 schema:isAccessibleForFree false
43 schema:isPartOf N8a78565d591c48d99b78135386cbad63
44 Nc486717fdeb24ecd9a30d480d7c5cf61
45 sg:journal.1094201
46 schema:name Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors
47 schema:pagination 445-454
48 schema:productId N0c409beece8e410ba11111c2aa426024
49 N5855428d3fcc4156bf51f72881f4f7d7
50 N99098a575d4646ba9860d32b9a48564a
51 Nc3db515bb0ef4817800f3308df8c41e9
52 Nf289a67a2fa345f38a40633821473df6
53 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011874287
54 https://doi.org/10.1007/s10637-008-9142-3
55 schema:sdDatePublished 2019-04-15T09:19
56 schema:sdLicense https://scigraph.springernature.com/explorer/license/
57 schema:sdPublisher N0167a30d134d4d9da53c2879bba23f28
58 schema:url http://link.springer.com/10.1007%2Fs10637-008-9142-3
59 sgo:license sg:explorer/license/
60 sgo:sdDataset articles
61 rdf:type schema:ScholarlyArticle
62 N0167a30d134d4d9da53c2879bba23f28 schema:name Springer Nature - SN SciGraph project
63 rdf:type schema:Organization
64 N06ca50af1e6544b0890ac64cbcf7304a rdf:first sg:person.01006242627.18
65 rdf:rest Nae3a2fd206f1481f85380376f70cc254
66 N0c409beece8e410ba11111c2aa426024 schema:name nlm_unique_id
67 schema:value 8309330
68 rdf:type schema:PropertyValue
69 N0d282af2738740d0914a7298c55ede19 rdf:first sg:person.01231377053.53
70 rdf:rest N48b4a5e53c6640e7a35b62a84c4015e7
71 N10b8ee3a668f46718512b14e953915e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Administration, Oral
73 rdf:type schema:DefinedTerm
74 N11433bf6796a489b8fe4221ab5e2583c rdf:first sg:person.016444546257.55
75 rdf:rest N85c72999bf394534bd060dfc21c166ed
76 N1311e2da408c4c219674362ecb84eb9f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Aged
78 rdf:type schema:DefinedTerm
79 N2329152b72384a4690fda62444762aa9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Aged, 80 and over
81 rdf:type schema:DefinedTerm
82 N2e1057ef6835405baa20da585875e81a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Antineoplastic Agents
84 rdf:type schema:DefinedTerm
85 N311fac97838f47d88baaa73a2f57533e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Drug Administration Schedule
87 rdf:type schema:DefinedTerm
88 N48b4a5e53c6640e7a35b62a84c4015e7 rdf:first sg:person.01051756026.25
89 rdf:rest Nb51d298fc6df459ba5873c475645cf6b
90 N5855428d3fcc4156bf51f72881f4f7d7 schema:name dimensions_id
91 schema:value pub.1011874287
92 rdf:type schema:PropertyValue
93 N5870ad86ceda49dd9f306ec27fd6493d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Male
95 rdf:type schema:DefinedTerm
96 N6f3e2579bbd44c9bab0760da9a1df036 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Trifluridine
98 rdf:type schema:DefinedTerm
99 N85c72999bf394534bd060dfc21c166ed rdf:first sg:person.0645263515.62
100 rdf:rest rdf:nil
101 N87d5693eb5024cc7b880533a6ae5c6a0 rdf:first sg:person.015275452707.07
102 rdf:rest Na47b616628ee4480bb63078859e2a983
103 N8a78565d591c48d99b78135386cbad63 schema:volumeNumber 26
104 rdf:type schema:PublicationVolume
105 N8fe584601a83400cbfcc48dda21fb2e7 rdf:first sg:person.0635347013.76
106 rdf:rest N11433bf6796a489b8fe4221ab5e2583c
107 N99098a575d4646ba9860d32b9a48564a schema:name readcube_id
108 schema:value 3893836ec0ba774403f525af3d26a7a8faa1b78f5d4639f8dcdc13e77c3ca8bf
109 rdf:type schema:PropertyValue
110 Na47b616628ee4480bb63078859e2a983 rdf:first sg:person.01144105331.55
111 rdf:rest Nf74b429c0f1c4440a45080c4a9065a63
112 Na5a12c413a88432fa1e20e8c95e06674 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Humans
114 rdf:type schema:DefinedTerm
115 Naba4d4793ad640c8923582504ece4367 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Neoplasms
117 rdf:type schema:DefinedTerm
118 Nae2bf377506e4a01b64c9cd1aac35094 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Drug Combinations
120 rdf:type schema:DefinedTerm
121 Nae3a2fd206f1481f85380376f70cc254 rdf:first sg:person.01133335751.97
122 rdf:rest N8fe584601a83400cbfcc48dda21fb2e7
123 Nb51d298fc6df459ba5873c475645cf6b rdf:first sg:person.01320500077.48
124 rdf:rest N87d5693eb5024cc7b880533a6ae5c6a0
125 Nb5826843b39649e5a1dc6ecd892a843e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Uracil
127 rdf:type schema:DefinedTerm
128 Nc3db515bb0ef4817800f3308df8c41e9 schema:name pubmed_id
129 schema:value 18528634
130 rdf:type schema:PropertyValue
131 Nc486717fdeb24ecd9a30d480d7c5cf61 schema:issueNumber 5
132 rdf:type schema:PublicationIssue
133 Nc4aa3506e14f4835b8de803cfd83ac54 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Adult
135 rdf:type schema:DefinedTerm
136 Nd7c47d5bdd2748338a14d626d3602e4b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Maximum Tolerated Dose
138 rdf:type schema:DefinedTerm
139 Ndbd43bc5390a4e0a88abe7261be5d070 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Middle Aged
141 rdf:type schema:DefinedTerm
142 Nf289a67a2fa345f38a40633821473df6 schema:name doi
143 schema:value 10.1007/s10637-008-9142-3
144 rdf:type schema:PropertyValue
145 Nf5de1b83de6f46138d478b9f6a704ff8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Female
147 rdf:type schema:DefinedTerm
148 Nf74b429c0f1c4440a45080c4a9065a63 rdf:first sg:person.0740127427.51
149 rdf:rest N06ca50af1e6544b0890ac64cbcf7304a
150 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
151 schema:name Medical and Health Sciences
152 rdf:type schema:DefinedTerm
153 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
154 schema:name Clinical Sciences
155 rdf:type schema:DefinedTerm
156 sg:journal.1094201 schema:issn 0167-6997
157 1573-0646
158 schema:name Investigational New Drugs
159 rdf:type schema:Periodical
160 sg:person.01006242627.18 schema:affiliation https://www.grid.ac/institutes/grid.419828.e
161 schema:familyName Mita
162 schema:givenName Akira
163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006242627.18
164 rdf:type schema:Person
165 sg:person.01051756026.25 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
166 schema:familyName Varadhachary
167 schema:givenName Gauri
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051756026.25
169 rdf:type schema:Person
170 sg:person.01133335751.97 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
171 schema:familyName Wolff
172 schema:givenName Robert A.
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133335751.97
174 rdf:type schema:Person
175 sg:person.01144105331.55 schema:affiliation https://www.grid.ac/institutes/grid.419828.e
176 schema:familyName Fukushima
177 schema:givenName Masakazu
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01144105331.55
179 rdf:type schema:Person
180 sg:person.01231377053.53 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
181 schema:familyName Overman
182 schema:givenName Michael J.
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231377053.53
184 rdf:type schema:Person
185 sg:person.01320500077.48 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
186 schema:familyName Kopetz
187 schema:givenName Scott
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320500077.48
189 rdf:type schema:Person
190 sg:person.015275452707.07 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
191 schema:familyName Thomas
192 schema:givenName Melanie B.
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015275452707.07
194 rdf:type schema:Person
195 sg:person.016444546257.55 schema:affiliation https://www.grid.ac/institutes/grid.477919.5
196 schema:familyName Xiong
197 schema:givenName Henry
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016444546257.55
199 rdf:type schema:Person
200 sg:person.0635347013.76 schema:affiliation https://www.grid.ac/institutes/grid.413471.4
201 schema:familyName Hoff
202 schema:givenName Paulo M.
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0635347013.76
204 rdf:type schema:Person
205 sg:person.0645263515.62 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
206 schema:familyName Abbruzzese
207 schema:givenName James L.
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645263515.62
209 rdf:type schema:Person
210 sg:person.0740127427.51 schema:affiliation https://www.grid.ac/institutes/grid.419828.e
211 schema:familyName Kuwata
212 schema:givenName Keizo
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740127427.51
214 rdf:type schema:Person
215 sg:pub.10.1007/bf02490095 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022217340
216 https://doi.org/10.1007/bf02490095
217 rdf:type schema:CreativeWork
218 sg:pub.10.1007/s00280-005-0033-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022076717
219 https://doi.org/10.1007/s00280-005-0033-4
220 rdf:type schema:CreativeWork
221 sg:pub.10.1007/s002800000243 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047992042
222 https://doi.org/10.1007/s002800000243
223 rdf:type schema:CreativeWork
224 sg:pub.10.1007/s002800050043 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030921918
225 https://doi.org/10.1007/s002800050043
226 rdf:type schema:CreativeWork
227 sg:pub.10.1038/nrc1074 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012947440
228 https://doi.org/10.1038/nrc1074
229 rdf:type schema:CreativeWork
230 https://app.dimensions.ai/details/publication/pub.1080229750 schema:CreativeWork
231 https://doi.org/10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049278910
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1002/cncr.22125 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002118474
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1016/s0959-8049(98)00058-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004034553
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1097/00001813-200503000-00007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028679966
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1111/j.1349-7006.2007.00477.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1033925038
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1200/jco.1992.10.6.896 schema:sameAs https://app.dimensions.ai/details/publication/pub.1076886243
242 rdf:type schema:CreativeWork
243 https://doi.org/10.2174/1568011043482089 schema:sameAs https://app.dimensions.ai/details/publication/pub.1069191995
244 rdf:type schema:CreativeWork
245 https://doi.org/10.3892/ijmm.13.2.249 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071505637
246 rdf:type schema:CreativeWork
247 https://doi.org/10.3892/ijmm.13.4.545 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071505677
248 rdf:type schema:CreativeWork
249 https://doi.org/10.3892/ijo.25.3.571 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071515444
250 rdf:type schema:CreativeWork
251 https://doi.org/10.3892/ijo.27.2.449 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071515804
252 rdf:type schema:CreativeWork
253 https://doi.org/10.3892/or.11.2.381 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071529095
254 rdf:type schema:CreativeWork
255 https://www.grid.ac/institutes/grid.240145.6 schema:alternateName The University of Texas MD Anderson Cancer Center
256 schema:name Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston Texas, 1515 Holcombe Blvd., 77030, Houston, TX, USA
257 rdf:type schema:Organization
258 https://www.grid.ac/institutes/grid.413471.4 schema:alternateName Hospital Sírio-Libanês
259 schema:name Centro Oncológico de Hospital Sirio-Libanés, Sao Paulo, Brazil
260 rdf:type schema:Organization
261 https://www.grid.ac/institutes/grid.419828.e schema:alternateName Taiho Pharmaceutical (Japan)
262 schema:name Taiho Pharmaceutical Co. LTD., Tokyo, Japan
263 rdf:type schema:Organization
264 https://www.grid.ac/institutes/grid.477919.5 schema:alternateName Center for Cancer and Blood Disorders
265 schema:name The Center for Cancer and Blood Disorders, ForthWorth, Texas, USA
266 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...